Brief: Abbisko Cayman Reaches License Agreement With Merck For Pimicotinib

Abbisko Cayman

04/12/2023 14:39

Dec 4 (Reuters) - Abbisko Cayman Ltd  2256.HK :
    * ABBISKO REACHED A LICENSE AGREEMENT WITH MERCK FOR
PIMICOTINIB
    * UNIT ENTERED INTO A LICENSE AGREEMENT WITH MERCK
HEALTHCARE KGAA
    * UNDER AGREEMENT, MERCK WILL BE GRANTED EXCLUSIVE LICENSE
TO
COMMERCIALIZE PRODUCTS COMPRISING OR CONTAINING PIMICOTINIB
    * UNDER DEAL, ABBISKO THERAPEUTICS WILL RETAIN EXCLUSIVE
RIGHTS TO
DEVELOP PIMICOTINIB WITHIN LICENSED TERRITORY
    * LICENSE TO COMMERCIALIZE PRODUCTS CONTAINING PIMICOTINIB
FOR ALL
INDICATIONS IN CHINESE MAINLAND, HONG KONG, MACAU, TAIWAN
    * PURSUANT TO AGREEMENT, ABBISKO THERAPEUTICS WILL RECEIVE A
ONE-TIME, NON-REFUNDABLE UPFRONT PAYMENT OF US$70 MILLION


Further company coverage:  2256.HK 

 ((Reuters.Briefs@thomsonreuters.com;))